Yuichiro Kikawa, Breast oncologist at Kansai Medical University, shared a post on X:
“Proud to share our study from Japan’s phase 3 RESQ trial estimating MIDs for EORTC QLQ-C30/BR23 in HER2− metastatic BC.
- First MID estimates for QLQ-BR23
- Expanded QLQ-C30 benchmarks
Excellent presentation by Dr. Aoyama—clear and impactful.”
More posts about ESMOAsia25.